Fluorouracil implant

Pharmacological Action Fluorouracil is an antimetabolite antitumor drug. It mainly acts on the S phase of the cell proliferation cycle and also kills cells in other phases. This product needs to be converted into 5-fluorouracil nucleotide to exert its antitumor activity. Its mechanism of action is to inhibit DNA synthesis by inhibiting thymine nucleotide synthetase. In addition, this product also has a certain inhibitory effect on RNA synthesis. Toxicological studies have not conducted this test and there are no reliable references.

Chemical name: 5-fluoro-2,4 (1H, 3H)-pyrimidinedione Chemical structure: Molecular formula: C4H3FN2O2 Molecular weight: 130.08

This product is white or off-white cylindrical granules.

Mainly used for esophageal cancer, colorectal cancer, gastric cancer, etc.

(1) Palliative chemotherapy for elderly patients with advanced cancer: implant 0.2g/m2 subcutaneously once according to body surface area, once every 10 days, twice in a row with a 10-day break as a course of treatment or follow the doctor's advice. (2) Combined chemotherapy: implant 0.5g/m2 of body surface area each time, repeat every three weeks, two to four times as a course of treatment or follow the doctor's advice. (3) Implantation of surface tumors or during surgery: 0.2~0.5g/m2 once, or follow the doctor's advice. Usage: Subcutaneous administration (1) The inner and outer sides of the patient's upper arms, the abdominal wall of both lower abdomens and other areas where drugs can be implanted are used as the drug area (see Figure 1a, 1b). The implantation area should be free of acute or chronic skin diseases and nodules. (2) After routine disinfection of the implantation area, use 0.5% lidocaine to perform radial tissue infiltration anesthesia in the implantation area. The infiltration range depends on the size of the implantation area. (3) After local anesthesia, hold the special implant needle and slowly insert the needle along the deep fascia and muscle (see Figure 2). After puncturing 3~5cm, withdraw the implant needle 1cm and implant 20mg of this drug (the amount of one tube); withdraw the implant needle 1cm again to implant the second 20mg. One implant channel should not exceed 80mg. (4) After completing the implantation of the first implant channel, puncture the second implant channel in a radial pattern (see Figure 3). The implantation procedure is the same as (3). (5) There are 5~6 implant channels distributed radially in one implant area. The total amount of implanted drugs in each implant area shall not exceed 0.46g in the abdomen and 0.3g in the upper arm. (6) After the implantation is completed, press the puncture point with a 75% alcohol cotton ball for 1~2 minutes and protect the wound with a Band-Aid.

1. Mild adverse reactions such as loss of appetite and leukopenia may be observed during the clinical application of this product. However, as the dose increases, adverse reactions similar to those of fluorouracil injection may occur, such as nausea, vomiting, oral mucositis, diarrhea, hair loss, and thrombocytopenia. 2. Local adverse reactions (1) When the dosage per implant channel exceeds 80 mg, redness, swelling, induration, and mild pain may occur at the implant site. These usually occur on the 4th to 8th day after implantation and gradually disappear on their own after 8th to 15th day. (2) When the dosage per implant channel exceeds 0.15 g, moderate pain and local ulcers may occur at the implant site. These usually occur on the 4th to 10th day after implantation and recover in about 20th to 60th day. (3) When the subcutaneous implant is too shallow, the above adverse reactions may be aggravated. After about two weeks, the skin

It is contraindicated for patients who are allergic to the ingredients of this product, those with chickenpox or herpes zoster, those with bone marrow suppression and pregnant women.

Precautions for children: This test has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Pregnant women are prohibited. Due to the potential mutagenicity, teratogenicity or carcinogenicity of this tablet and the possible toxicity and side effects in infants, breastfeeding is not allowed during the use of this product.

1. Allopurinol can reduce the bone marrow suppression caused by fluorouracil. 2. Cimetidine can increase the area under the concentration-time curve of fluorouracil and reduce the clearance rate of this product. 3. It has been reported that methotrexate, metronidazole and folate may affect the anti-cancer efficacy and toxicity of fluorouracil.

Keep away from light and store in airtight container.

0.1g

36 months